# NCT06561607 (NCT06561607)

> A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06561607
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions: Breast Cancer
- Interventions: TQB2102 for Injection; Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
- Enrollment: 542
- Primary outcome: Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 9

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06561607

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06561607", "email": "<work email>"}; the inbox owner confirms by the emailed link.